Baricitinib: all 150 studies that test it
Page 2 of 2. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.
- INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic DrugsCompletedNCT00902486Phase 2Results posted
- Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African DescentCompletedNCT07843732Phase 2
- Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.CompletedNCT07645430Not applicable
- Baricitinib for Refractory Takayasu ArteritisCompletedNCT06662721Phase 2
- Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary InjuryActive, not recruitingNCT06548802Phase 1/2
- Retinol Binding Protein 4 Protein in Alopecia Areata Treated With BarcitinibActive, not recruitingNCT06545110Phase 1
- Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With HemoblastosisActive, not recruitingNCT06475820Phase 2/3
- A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)Active, not recruitingNCT06240351Phase 4
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept StudyActive, not recruitingNCT06158113Phase 2
- Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT05969730Not applicable
- REVERSE-Long COVID-19 With Baricitinib StudyWithdrawnNCT05858515Phase 3
- Baricitinib in Idiopathic Granulomatous MastitisActive, not recruitingNCT05852171Phase 2
- Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical TrialStatus unknownNCT05827497Phase 4
- Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT05792462Phase 1
- Use of Baricitenib to Maintain of RemissionStatus unknownNCT05686746Phase 2/3
- Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid ArthritisCompletedNCT05660655Phase 4
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)CompletedNCT05524311Phase 2
- Baricitinib for Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownNCT05446831Phase 2
- Baricitinib for Cutaneous DermatomyositisWithdrawnNCT05361109Phase 2
- A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic SclerosisActive, not recruitingNCT05300932Phase 4
- Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19Status unknownNCT05279391Not applicable
- BARIcitinib Cognitive Emotional and Neural signaTuRETerminatedNCT05238896Phase 4
- Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney DiseaseCompletedNCT05237388Phase 2
- Tocilizumab Versus Baricitinib in Patients With Severe COVID-19CompletedNCT05082714Not applicable
- COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
- Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Status unknownNCT05056558Phase 3
- Efficacy and Safety of Baricitinib in Sjogren's SyndromeCompletedNCT05016297Phase 2
- Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)CompletedNCT05006768Phase 1
- Baricitinib in Hospitalized Covid-19 Patients With Diabetes MellitusWithdrawnNCT04970719Phase 3
- A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome PatientsCompletedNCT04916756Phase 1/2
- Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)CompletedNCT04901325Phase 2
- EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform TrialTerminatedNCT04891133Phase 2/3
- Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoCompletedNCT04822584Phase 2
- Baricitinib in New-onset Type 1 DiabetesCompletedNCT04774224Phase 2
- Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 PatientsStatus unknownNCT04693026Phase 3
- Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic TrialStatus unknownNCT04399798Phase 2
- Baricitinib Compared to Standard Therapy in Patients With COVID-19Status unknownNCT04393051Phase 2
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Status unknownNCT04390464Phase 4
- Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19TerminatedNCT04373044Phase 2
- Baricitinib Therapy in COVID-19CompletedNCT04358614Phase 2/3
- Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Status unknownNCT04346147Phase 2
- Safety and Efficacy of Baricitinib for COVID-19WithdrawnNCT04340232Phase 2/3
- Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsActive, not recruitingNCT04321993Phase 2
- Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.Status unknownNCT04320277Phase 2/3
- JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIMCompletedNCT04208464Phase 2
- Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT04131738Phase 1
- A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Active, not recruitingNCT04088396Phase 3
- BAriCitinib Healing Effect in earLy pOlymyalgia RheumaticaCompletedNCT04027101Phase 2
- Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male SubjectsCompletedNCT03945760Early Phase 1
- Effect of Baricitinib Treatment on Peripheral Bone in RAStatus unknownNCT03701789Phase 3